- Home
- SCLX vs VIVK Comparison
SCLX vs VIVK Comparison
Compare SCLX & VIVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- VIVK
- Stock Information
- Founded
- SCLX 2011
- VIVK 2006
- Country
- SCLX United States
- VIVK United States
- Employees
- SCLX N/A
- VIVK N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- VIVK Oilfield Services/Equipment
- Sector
- SCLX Health Care
- VIVK Energy
- Exchange
- SCLX Nasdaq
- VIVK Nasdaq
- Market Cap
- SCLX 35.7M
- VIVK 38.4M
- IPO Year
- SCLX N/A
- VIVK N/A
- Fundamental
- Price
- SCLX $13.63
- VIVK $1.11
- Analyst Decision
- SCLX Strong Buy
- VIVK
- Analyst Count
- SCLX 3
- VIVK 0
- Target Price
- SCLX $367.50
- VIVK N/A
- AVG Volume (30 Days)
- SCLX 225.6K
- VIVK 199.2K
- Earning Date
- SCLX 08-12-2025
- VIVK 08-15-2025
- Dividend Yield
- SCLX N/A
- VIVK N/A
- EPS Growth
- SCLX N/A
- VIVK N/A
- EPS
- SCLX N/A
- VIVK N/A
- Revenue
- SCLX $50,710,000.00
- VIVK $111,130,140.00
- Revenue This Year
- SCLX $68.30
- VIVK N/A
- Revenue Next Year
- SCLX $124.48
- VIVK N/A
- P/E Ratio
- SCLX N/A
- VIVK N/A
- Revenue Growth
- SCLX 7.79
- VIVK 85.84
- 52 Week Low
- SCLX $3.60
- VIVK $0.55
- 52 Week High
- SCLX $57.75
- VIVK $2.29
- Technical
- Relative Strength Index (RSI)
- SCLX 65.59
- VIVK 63.59
- Support Level
- SCLX $10.14
- VIVK $0.80
- Resistance Level
- SCLX $17.76
- VIVK $1.30
- Average True Range (ATR)
- SCLX 1.79
- VIVK 0.11
- MACD
- SCLX 0.52
- VIVK 0.03
- Stochastic Oscillator
- SCLX 57.45
- VIVK 59.72
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.